In Vitro Diagnostics Market Global Analytical Study, Growth Strategies, Size, Product Type, End User, Geography And Competitive Analysis
The global in vitro
diagnostics market size is expected to reach USD 113.9 billion by
2027, according to a new report by Grand View Research, Inc. The market is
expected to expand at a CAGR of 4.5% from 2021 to 2027. The
growth is driven by the growing geriatric population and technological advancements
in diagnostics that are supporting its adoption.
Technological advancements in terms of accuracy, portability,
and cost-effectiveness are expected to be one of the high impact rendering
drivers of this market. For instance, in June 2017, Agena Bioscience launched
the MassARRAY system integrated with CHIP Prep Module in Europe. The system was
marketed as a CE-IVD product under Directive 98/79/EC. Moreover, Real-Time
Polymerase Chain Reaction (qPCR) is one of the fastest-growing application
segments of the in vitro diagnostics (IVD) market.
Key Insights &
Findings from the report:
- Molecular diagnostics is expected
to witness the fastest growth over the forecast period.
- High use of reagents in IVD
testing, high demand for over-the-counter diagnostic tests, and increase
in adoption of these tests in nonmedical facilities, such as home, are
some of the factors that are driving the growth, providing it a clinical
advantage over other IVD tests.
- Reagents held the largest market
share in 2020 owing to the increasing demand for genetic testing and
availability of technologically advanced cancer diagnostic tests in
countries with unmet clinical needs, such as India and Middle East &
Africa.
- The growing availability of
CE-IVD certified kits globally to diagnose and screen patients during
epidemic situations is expected to boost the growth of reagents and
instruments segments.
- Key players are updating their
range of testing options for qPCR instruments by undertaking R&D
initiatives for the development of kits that target emerging diseases, or
by entering into agreements with other kit manufacturing companies.
In Vitro Diagnostics
Market Growth & Trends
The IVD market is highly competitive in nature. Consequently,
manufacturers are required to improvise products in terms of specificity,
accuracy, precision, speed, and other parameters, in order to gain an advantage
over previously marketed products.
A steady rise in consumer awareness about diagnosing infectious
diseases and increasing disease prevalence, especially in developing and
under-developed countries, are driving the market penetration of the products.
For instance, in February 2019, Abbott received CE Mark for DETERMINE HBSAG 2
test for detection and diagnosis of hepatitis B surface antigen.
Organizations promote funding to support R&D and product
development exercises pertaining to clinical diagnostics. For instance, Vela
Diagnostics received USD 225,000 as Biomedical Advanced Research and
Development Authority (BARDA) fund to develop COVID-19 tests. Moreover, the
introduction of the American Health Care Act of 2017 is expected to improve the
healthcare of the U.S. Rising government initiatives pertaining to the
importance of IVD will fuel market growth.
The presence of effective technologies such as molecular
diagnostics is expected to reduce the threat of substitutes. Moreover, their
contribution in the field of genetic testing is of paramount importance and,
therefore, experience a low threat of substitutes. However, high prices of
these tests are expected to encourage patients to shift to external
substitutes.
Major players in the market are Roche Diagnostics; Becton
Dickinson; Abbott Laboratories; Siemens; and bioMerieux, which are
well-established. Therefore, local companies and new organizations have little
scope to enter the market and ensure sustainability. However, companies such as
Danaher Corporation and Hologic have successfully excelled in the market
through mergers and acquisitions. The seed capital required is high.
In Vitro Diagnostics
Market Segmentation
Grand View Research has segmented the global in-vitro
diagnostics market based on the product, technology, application, end-use, and
region:
In Vitro Diagnostics
Product Outlook (Revenue, USD Million, 2016 - 2027)
- Instruments
- Reagents
- Services
In Vitro Diagnostics
Technology Outlook (Revenue, USD Million, 2016 - 2027)
- Immunoassay
- Instruments
- Reagents
- Services
- Hematology
- Instruments
- Reagents
- Services
- Clinical Chemistry
- Instruments
- Reagents
- Services
- Molecular Diagnostics
- Instruments
- Reagents
- Services
- Coagulation
- Instruments
- Reagents
- Services
- Microbiology
- Instruments
- Reagents
- Services
- Others
- Instruments
- Reagents
- Services
In Vitro Diagnostics
Application Outlook (Revenue, USD Million, 2016 - 2027)
- Infectious Disease
- Diabetes
- Oncology
- Cardiology
- Nephrology
- Autoimmune Disease
- Drug testing
- Others
In Vitro Diagnostics
End-use Outlook (Revenue, USD Million, 2016 - 2027)
- Hospitals
- Laboratories
- Home Care
- Others
In Vitro Diagnostics
Regional Outlook (Revenue, USD Million, 2016 - 2027)
- North America
- U.S.
- Canada
- Europe
- U.K.
- Germany
- France
- Italy
- Spain
- Russia
- Asia Pacific
- Japan
- China
- India
- South Korea
- Singapore
- Australia
- Latin America
- Brazil
- Argentina
- Mexico
- Middle East & Africa
- South Africa
- Saudi Arabia
- UAE
List of Key Players
of In Vitro Diagnostics Market
- Abbott
- Danaher
- bioMérieux SA
- Bio-Rad Laboratories, Inc.
- Becton, Dickinson and Company
- Siemens Healthineers AG
- QIAGEN
- Quidel Corporation
- F. Hoffmann-La Roche AG
- Sysmex Corporation
- Charles River Laboratories
International, Inc.
- Quest Diagnostics
- Agilent Technologies
Read More @ https://www.futuremarketinsights.com/reports/in-vitro-diagnostics-market
Comments
Post a Comment